NEWS RELEASE

PerkinElmer Launches Industry First No-Wash Immunoassay For Phospho Ubiquitin Ser65 to Help Drive Neuroscience Disease and Therapeutics Research Forward

10/26/2020

PDF Version

New kit provides highly sensitive and efficient approach for studying mitophagy impairment in conditions such as Parkinson's and Alzheimer's

WALTHAM, Mass. – October 26, 2020 – **PerkinElmer, Inc.**, a global leader committed to innovating for a healthier world, today launched the life science industry's first no wash Ubiquitin phosphorylation at Serine 65 immunoassay for studying defective mitophagy biological mechanisms that have been broadly associated with diseases such as Parkinson's and Alzheimer's. The **new PerkinElmer Cisbio HTRF® Phospho-Ubiquitin (Ser65) Cellular Kit** takes analysis efficiency and accuracy to the next level compared to existing techniques such as Western blot and is aimed at helping scientists discover new therapeutic candidates earlier in the disease cycle.

The innovative assay leverages TR-FRET technology to bring high sensitivity across a wide range of analytes and greater study specificity to the Phospho-Ubiquitin (Ser65) intersection point that has been shown to play a key role in mitophagy dysfunction and breakdowns in the complex network between neurons and glial cells which can lead to neurodegenerative disease.

Efficient and streamlined workflows and accelerated data delivery are also provided by the immunoassay's mix and

read method approach and compatibility with microplate readers such as PerkinElmer's **VictorTM Nivo®** or **EnVision®** systems. Analysis can also be automated and run in high throughput formats.

"With over 70 Million people around the world living with Alzheimer's and Parkinson's and the sheer complexity of how neurodegenerative disease develops in the brain, it is critical that scientists have the tools they need to help unlock promising avenues of study such as modulating mitophagy impairment," said Alan Fletcher, VP and GM of Life Sciences, PerkinElmer. "With this new immunoassay, researchers now have a more efficient and effective way to study a key biomarker which could lead to exciting new therapeutic candidates."

The new PerkinElmer Cisbio HTRF Phospho-Ubiquitin (Ser65) Cellular Kit, joins PerkinElmer's range of immunoassay kits and reagents for neuroscience applications across HTRF, Alpha, LANCE® and DELFIA®. For more information please visit: **https://learn.cisbio.com/lp/guide-neurodegenerative-diseases-and-neuroinflammation-pathways**; **https://uk.cisbio.eu/dd/by-universe/neuroscience**

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at **www.perkinelmer.com**.

Media Contact
Jennifer McNeil
+1 508 380 2902
Jennifer.mcneil@perkinelmer.com